Tvardi Therapeutics

Company snapshot

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Tvardi Therapeutics. Not investment advice.

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 50

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  Syndax Pharmaceuticals

  TA overlap score 29.4

• Peer + 0 momentum

  CASI Pharmaceuticals

  TA overlap score 24.4

• Peer + 0 momentum

  Shandong Topscience Biotech

  TA overlap score 20.6

Recent activity

Latest pipeline, patent, and corporate events for Tvardi Therapeutics.

1. Jun 5, 2026 Clinical update

   Control Group — Phase 1

2. May 23, 2026 Clinical update

   TTI-101 — Phase 2

3. May 23, 2026 Clinical update

   TTI-101 — Phase 2

4. May 23, 2026 Clinical update

   TTI-101 — Phase 2

5. May 23, 2026 Clinical update

   TTI-101 — Phase 1

View all clinical trial activity →

• What is Tvardi Therapeutics?

  Tvardi Therapeutics is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker TVRD. Primary therapeutic focus areas include Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Idiop

• Is Tvardi Therapeutics publicly traded?

  Yes. Tvardi Therapeutics is listed with ticker TVRD on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Tvardi Therapeutics develop or market?

  We link 2 drug profile(s) where Tvardi Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/tvardi-therapeutics#company-drugs.

• What are the latest developments for Tvardi Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Tvardi Therapeutics focus on?

  Tvardi Therapeutics focuses on Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Head and Neck Squamous Cell Carcinoma based on our analysis of their pipeline programs and drug development activities.